Back to Results

Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT00838435

Condition

Phenylketonuria

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

This multicenter, open label study is designed to evaluate the safety of Kuvan® and its effect on neurocognitive function, blood Phe concentration, and growth in children with PKU who are 0-6 years old.

Eligibility Criteria

Birth Sex

All

Age

Up to 6 Years

Healthy Volunteers

No

Drug/Treatment:

sapropterin dihydrochloride

Phase:

Phase 3

Study Type:

Interventional

Number of Participants:

95

Study Started:

2009-02

Study Updated:

2020-12-22

Trial Locations

  • La Jolla, California, United States

  • Orange, California, United States

  • Tampa, Florida, United States

  • Chicago, Illinois, United States

  • Boston, Massachusetts, United States

  • Kansas City, Missouri, United States

  • Cleveland, Ohio, United States

  • Columbus, Ohio, United States

  • Hershey, Pennsylvania, United States

  • Nashville, Tennessee, United States

  • Salt Lake City, Utah, United States

  • Milwaukee, Wisconsin, United States

  • Edmonton, Alberta, Canada

  • Vancouver, British Columbia, Canada

  • Winnipeg, Manitoba, Canada

  • Hamilton, Ontario, Canada

  • Toronto, Ontario, Canada

  • Montreal, Quebec, Canada

  • Sainte-Foy, Quebec, Canada

Inclusion Criteria

  • Established diagnosis of PKU with hyperphenylalaninemia (HPA) documented in the medical record by at least 2 blood Phe concentrations greater than or equal to 360 micromole/L (6 mg/dL) taken at least 3 days apart
  • Documented blood Phe control (defined by the standard used at each treatment center) prior to study enrollment, if applicable (eg, the subject is old enough for these data to be collected); blood Phe concentrations for subjects < 6 months old at Screening must be considered controlled and stable by the Investigator
  • Willing to adhere to a prescribed Phe restricted diet in order to maintain blood Phe concentrations within the recommended ranges established at the subject’s study site
  • Age 0 to 6 years old, inclusive, at Screening
  • Parent(s) or guardian(s) willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
  • Parent(s) or guardian(s) willing and able to comply with all study procedures
  • Female subjects of childbearing potential (as determined by the investigator) and sexually mature male subjects willing to use a medically accepted method of contraception throughout the study. Female subjects of childbearing potential willing to undergo periodic pregnancy tests during the course of the study

Exclusion Criteria

  • Established diagnosis of primary tetrahydrobiopterin (BH4) deficiency
  • Known hypersensitivity to Kuvan or its excipients
  • History of organ transplantation
  • Perceived to be unreliable or unavailable for study participation or to have parents or legal guardians who are perceived to be unreliable or unavailable
  • Use of methotrexate or other medications that inhibit folate metabolism
  • Serious neuropsychiatric illness (eg, major depression) not currently under medical control
  • Use of Kuvan or any investigational agent within 30 days prior to Screening, or known requirement for any investigational agent prior to completion of all scheduled study assessments
  • Concurrent disease or condition that would interfere with study participation or safety (eg, seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin dependent diabetes)
  • Any condition that, in the view of the Principal Investigator (PI), renders the subject at high risk for failure to comply with treatment or to complete the study
  • Use of phosphodiesterase type 5 (PDE5) inhibitor

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us